Noble Life Science Partners
    Nathan Cali

    Press Releases

    Aequus announces the issuance of stock options

    Aequus Provides Third Quarter 2017 Operational Highlights

    Aequus Granted European Patent for Once-Weekly Transdermal Aripiprazole

    Aequus Granted Chinese Patent for Once-Weekly Transdermal Aripiprazole

    Aequus Announces Positive Results for Proof of Concept Clinical Trial of Anti-Nausea Patch

    Aequus Provides Second Quarter 2017 Operational Highlights

    Aequus and Ehave Collaborate on Bioinformatics Platform for Management of Clinical Trials

    Aequus Announces Abbreviated Development Path for Transdermal Aripiprazole

    Aequus Receives Approval for Short Form Base Shelf Prospectus to Raise up to C$20,000,000

    Aequus Receives Approval from Health Canada to Initiate Proof of Concept Clinical Trial of Anti-Nausea Patch

    Aequus Advances Clinical Development of Transdermal Anti-Nausea Patch

    Santen and Aequus Enter Into a Commercial Collaboration in Canada

    Aequus Approves Advance Notice Policy

    Aequus Pharmaceuticals and CDRD Announce Research Collaboration to Improve Cannabinoid-Based Therapeutics

    Aequus Provides First Quarter 2017 Financial Highlights

    Aequus Validates Need for Improved Delivery Methods of Medical Cannabis

    Aequus Provides Fourth Quarter and Fiscal 2016 Financial Highlights

    Aequus Launches Medical Cannabis Physician Research in US and Canada

    Aequus Announces Upsizing of Previously Announced Bought Deal of Units to $4.5 Million

    Aequus Announces $3 Million Bought Deal Financing

    Aequus Licenses Rights to Cannabinoid Transdermal Patch to Treat Neurological Disorders

    Aequus Receives Non-Dilutive Funding from the Government of Canada to Support Aripiprazole Patch Development

    Aequus Initiates Second Proof of Concept Clinical Trial of Transdermal Aripiprazole Patch

    Aequus Obtains Public Reimbursement for Vistitan in Two Additional Provinces: Alberta and Manitoba

    Aequus Provides Q3 2016 Financial Highlights with Substantial Increase in Quarter over Quarter Revenues

    Aequus Prepares for Proof of Concept Clinical Study for Transdermal Anti-Nausea Diclegis Program

    Aequus Advances Clinical Development of Transdermal Aripiprazole Patch

    Aequus Partners with Camargo to Support US Regulatory Strategy for Development Programs

    Aequus Obtains Ontario Provincial Listing for Vistitan™

    Aequus Closes Financing for Gross Proceeds of C$2,743,920

    Aequus Pharmaceuticals Inc. Announces $2.0 to $4.0 Million Best Efforts Financing

    Aequus Provides Corporate Update on Commercial and Development Programs

    Aequus Announces Advancement of Anti-Nausea Transdermal Extended-Release Patent Application

    Aequus Announces Advancement of Clobazam Transdermal Patent Application

    Aequus appoints Ann Fehr as Chief Financial Officer

    Aequus Announces Stock Option Grant

    Aequus Pharmaceuticals Initiates Promotional Efforts for VISTITAN™ in Canada

    Aequus to Present at Bloom Burton & Co. Healthcare Investor Conference

    Aequus Awarded Growth Stage Life Sciences Company of the Year

    Aequus Licenses Canadian Commercialization Rights to Trokendi XR® and Oxtellar XR® from Supernus

    Aequus Announces Positive Results from Single-Dose Bioavailability Study of Aripiprazole Transdermal Patch

    Aequus Pharmaceuticals to Present at Noble Capital Markets’ Investor Conference

    Aequus Closes Previously Announced Equity Financings

    Aequus Announces Proposed Equity Financings of Up to C$2,750,000

    Aequus Announces Completion of Dosing in Phase 1 Clinical Trial of Aripiprazole Transdermal Patch

    Aequus Pharmaceuticals Initiates Promotional Efforts for Transplant Product in Canada

    Aequus Closes Financing for Gross Proceeds of C$1,237,500

    Aequus Announces Terms of Public Offering of Common Shares

    Aequus Announces Stock Option Grant

    Aequus Announces Proposed Offering of Common Shares

    Aequus Pharmaceuticals Announces Trading on OTCQB

    Aequus Pharmaceuticals Announces the Completion of the Acquisition of TeOra Health

    Positive Preclinical Results and Patent Allowed for Aequus’ Once-Weekly Transdermal Aripiprazole

    Aequus Announces Positive Skin Irritation Results for Once-Weekly Transdermal Aripiprazole

    Aequus Retains Investor Relations Representative

    Aequus and Corium Enter into Product Development Collaboration Focused on CNS

    Aequus Pharmaceuticals Lists on the TSX Venture Exchange and Appoints New Director

    Aequus Pharmaceuticals Receives Conditional Approval To Commence Trading On TSX-V Exchange

    Aequus Pharmaceuticals Becomes Reporting Issuer

    Aequus Pharmaceuticals Closes $4.2 Million Private Placement Financing